Eli Lilly and Company has reported second-quarter 2026 financial results that significantly surpassed Wall Street expectations, fueled by the relentless demand for its flagship GLP-1 injectable drugs, Mounjaro and Zepbound. The company announced revenue of $23.0 billion, a substantial 48% increase year-over-year, driven by strong volume growth in its key therapeutic areas. Earnings per share (EPS) came in at $8.38 on a non-GAAP basis, far exceeding the analyst consensus of $6.06.
This robust performance has led Lilly to raise its full-year 2026 revenue guidance to between $85 billion and $87 billion, signaling confidence in sustained market leadership. The company's GLP-1 franchise continues to be the primary growth engine, with Mounjaro and Zepbound sales combined accounting for a significant portion of total revenue. This sustained demand underscores the resilience of Lilly's injectable therapies, even as oral alternatives emerge in the market.
The widening gap between Lilly and its main competitor, Novo Nordisk, in the critical obesity and diabetes space was evident in the latest earnings. While Novo Nordisk also reported increased sales and raised its forecasts, Lilly's consistent outperformance in its injectable GLP-1 offerings continues to solidify its dominant position. Lilly's strategic investments in manufacturing expansion and a diverse pipeline across oncology, immunology, and neuroscience further reinforce its long-term growth trajectory, positioning it to potentially reach new market valuations.
